Echelon Biosciences成立于1997年10月3日，总部坐落于在美国犹他州。从1997到2004，EBI主要用于政府的补助金以及产品的销售收入来资助其研究工作。2005年初，EBI的依特钠Zentaris购买 （NAS：AEZS）的MEP抗感染，PI3激酶小分子程序，目录业务，与科学专业。2007年末，前沿科学公司（FSI）在洛根，犹他州购买了EBI， 专业从事卟啉和硼化学。自公司成立以来以来，EBI保留了开发研究试剂脂质新的检测方法。不断开拓**，从而推动药物研究的新发型。
Echelon Biosciences是美国杰出免疫学产品供应商，专业提供各种抗体、分析检测试剂盒、抑制剂等产品，尤其擅长以细胞信号、脂类代谢和标记物研究为主的相关产品。为研究治疗诸如癌症、糖尿病、炎症、感染和心脑血管疾病专家提供**有效工具。
Echelon Biosciences可提供PI3-Kinase实验解决全套方案，从分析服务到实验用抗体、酶和抑制剂等，**满足科研需求。
Lysolipid Pathway Synthetic Lysophosphatidic Acid (LPA)
◆Inhibitors抑制剂系列◆Labeled标记物系列
◆Ligands配体系列◆Ligands配体系列
◆Analogs类似物系列◆Saturated底物系列
◆Unsaturated不饱和系列
◆Sphingosine 1 Phosphate (S1P )鞘氨醇磷酸酯◆Sphingomyelin鞘磷脂 ◆FTY720P
Echelon Biosciences是世界上唯壹完整**提供Autotaxin(ATX)和Autotaxin(ATX)相关试剂的供应商。
Echelon Biosciences目的在于进一步发展的脂质的细胞信号转导的关键代谢酶的科学，它提供了对癌症，心血管疾病疾病，糖尿病，炎症，感染的潜在的药物和诊断发展的新的和可行的目标。
Echelon Biosciences为生命科学社区提供的产品包括： 抗体 分析检测试剂盒 抑制剂 细胞信号产品 脂类代谢 标记物
Z-R015 Anti-huVps34 （Class III PI3-Kinase） Antibody for IP
抗体 Z-R016 Anti-huVps34 （Class III PI3-Kinase） Antibody for WB K-1000 PI3-K ELISA Kit
试剂盒K-1000S PI3-K ELISA: Pico Assay
K-1100 PI3-K Fluorescence Polarization Kit
K-1300 PI3-K AlphaScreen
K-2700S TRueFRET PI3-K Activity Assay
K-3000 Class III PI3-K ELISA Kit P27-18H PI3-K （p-110 alpha/p85 alpha） Active Enzyme
酶P28-10H PI3-K （p-110 beta/p85 alpha） Active Enzyme
B-0021 Resveratrol （Class IA PI3-K Inhibitor）
抑制剂 B-0222 Wortmannin （PI3-Kinase Inhibitor）
B-0294 PI3-Kinase Inhibitor （LY294002）
B-0301 PI3-Kinase Gamma Inhibitor 1 （AS605240）
B-0302 PI3-Kinase Gamma Inhibitor 2 （AS604850
B-0303 PI3-Kinase Alpha Inhibitor 1 （PI-103）
B-0304 PI3-Kinase Alpha Inhibitor 2
Echelon Biosciences Incorporated (EBI) was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. Initially, Echelon BiosciencesEBI was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, with the aim to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.
From 1997 through 2004, Echelon BiosciencesEBI primarily used government grants and product sales revenues to fund its research efforts. In early 2005, EBI was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP anti-infectives, PI3-Kinase small molecule program, catalog business, and scientific expertise. In late 2007, Frontier Scientific Incorporated (FSI) based in Logan, Utah purchased EBI. Specializing in porphyrin and boron chemistry, FSI opened the doors for expanded research.
Since 1997, Echelon BiosciencesEBI has retained its commitment to developing novel *****s and reagents for lipid research and beyond. At EBI’s core is the desire to innovate, thus pushing medicinal research to new limits. We look forward to providing scientists around the world with the tools they need to cure human disease states for years to come and we welcome any suggestions about how we can better do so.